Skip to main content

Table 1 Clinical and microbiological characteristics of 28 breakthrough VSB cases

From: Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital

Characteristics

No.

Median age (range)

55 (20–71)

Gender

 

  Male

15 (53.6 %)

  Female

13 (46.4 %)

Hematological disorder

 

 Myeloid malignancy

 

  AML

3 (10.7 %)

  MDS overt AML

6 (21.4 %)

  MDS

8 (28.6 %)

  CML

1 (3.6 %)

 Lymphoid malignancy

 

  ALL

5 (17.9 %)

  NHL

1 (3.6 %)

  T-PLL

1 (3.6 %)

 Others

 

  Others

3 (10.7 %)

Hematopoietic stem cell transplantation

 

  CBT

22 (78.6 %)

  rPBSCT

4 (14.3 %)

  uBMT

2 (7.1 %)

Status of the patients

 

  Nosocomial infection

28 (100 %)

  Severe neutropenia (ANCs <100/pL )

28 (100 %)

  Receipt of beta-lactam in the previous 30 day

6 (21.4 %)

Clinical presentation

 

  Median body temperature (range) (°C)

38.6 (37.5-40.6)

  Acute respiratory distress syndrome

0

  Co-infection

9 (32.1 %)

Co-infectious pathogen

 

  Staphylococcus epidermidis

5

  Corynebacterium striatum

2

  Enterococcus faecium

1

  Rothia mucilaginosa

1

  Escherichia coli

1

Treatment

 

  Cefepime

26 (92.9 %)

  Piperacillin/tazobactam

2 (7.14 %)

  Empiric VCM administration

4 (14.3 %)

Clinical outcome

 

  Crude 30-day mortality

3 (10.7 %)

  Crude 60-day mortality

3 (10.7 %)

Clinical presentation of mono VSB

N = 19

  VGS shock syndrome

5 (26 %)

  1. AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic myelogenous leukemia, ALL acute lymphoblastic leukemia, NHL non Hodgkin lymphoma, T-PLL T-cell prolymphocytic leukemia, SAA severe aplastic anemia, CBT cord blood transplantation , rPBSCT related peripheral blood cell transplantation, uBMT unrelated bone marrow transplantation, ANCs absolute neutrophil counts, VCM vancomycin, VSB viridans streptococcal bacteremia, VGS viridans group streptococcus